Overview
This page summarizes trial-derived R&D investment signals for [Multiple System Atrophy (MSA)](/diseases/multiple-system-atrophy) using the local [Clinical Trials Index](/clinical-trials) pipeline snapshot refreshed on `2026-03-14T04:21:18`. The intent is to track portfolio concentration, sponsor mix, and underrepresented mechanism areas that can inform quarterly planning. [@clinicaltrialsgov]
Portfolio Metrics
| Metric | Value |
|---|---|
| Total tracked trials | 429 |
| Active trials (recruiting/active/not-yet-recruiting) | 153 (35.7%) |
| Completed trials | 189 (44.1%) |
| Late-stage representation (Phase 3/4) | 43 (10.0%) |
| Biomarker-forward programs | 28 (14.4%) |
| Combination-therapy signals | 0 (0.0%) |
Trial Status Distribution
Active vs Historical Summary
| Category | Trial Count | Share |
|---|---|---:|
| Active/Recruiting | 82 | 42.3% |
| Not Yet Recruiting | 4 | 2.1% |
| Recruiting | 55 | 28.4% |
| Active Not Recruiting | 18 | 9.3% |
| Enrolling By Invitation | 5 | 2.6% |
| Historical | 93 | 47.9% |
| Completed | 76 | 39.2% |
| Terminated | 14 | 7.2% |
| Withdrawn | 2 | 1.0% |
| No Longer Available | 1 | 0.5% |
| Unknown | 18 | 9.3% |
Key Insight: Approximately 42.3% of registered Multiple System Atrophy (MSA) trials are currently active, while 47.9% have reached a terminal status (completed, terminated, or withdrawn). The 18 unknown-status entries reflect trials with stale registry records.
12-Month Trial Activity Trend
...Overview
This page summarizes trial-derived R&D investment signals for [Multiple System Atrophy (MSA)](/diseases/multiple-system-atrophy) using the local [Clinical Trials Index](/clinical-trials) pipeline snapshot refreshed on `2026-03-14T04:21:18`. The intent is to track portfolio concentration, sponsor mix, and underrepresented mechanism areas that can inform quarterly planning. [@clinicaltrialsgov]
Portfolio Metrics
| Metric | Value |
|---|---|
| Total tracked trials | 429 |
| Active trials (recruiting/active/not-yet-recruiting) | 153 (35.7%) |
| Completed trials | 189 (44.1%) |
| Late-stage representation (Phase 3/4) | 43 (10.0%) |
| Biomarker-forward programs | 28 (14.4%) |
| Combination-therapy signals | 0 (0.0%) |
Trial Status Distribution
Active vs Historical Summary
| Category | Trial Count | Share |
|---|---|---:|
| Active/Recruiting | 82 | 42.3% |
| Not Yet Recruiting | 4 | 2.1% |
| Recruiting | 55 | 28.4% |
| Active Not Recruiting | 18 | 9.3% |
| Enrolling By Invitation | 5 | 2.6% |
| Historical | 93 | 47.9% |
| Completed | 76 | 39.2% |
| Terminated | 14 | 7.2% |
| Withdrawn | 2 | 1.0% |
| No Longer Available | 1 | 0.5% |
| Unknown | 18 | 9.3% |
Key Insight: Approximately 42.3% of registered Multiple System Atrophy (MSA) trials are currently active, while 47.9% have reached a terminal status (completed, terminated, or withdrawn). The 18 unknown-status entries reflect trials with stale registry records.
12-Month Trial Activity Trend
The following table shows trial status updates over the past 12 months, based on last update date in ClinicalTrials.gov:
| Month | Total Updates | Active/Recruiting | Historical |
|---|---|---:|---:|
| 2025-03 | 3 | 3 | 0 |
| 2025-04 | 7 | 5 | 2 |
| 2025-05 | 6 | 4 | 2 |
| 2025-06 | 7 | 6 | 1 |
| 2025-07 | 5 | 2 | 3 |
| 2025-08 | 2 | 0 | 2 |
| 2025-09 | 4 | 4 | 0 |
| 2025-10 | 4 | 4 | 0 |
| 2025-11 | 6 | 5 | 1 |
| 2025-12 | 6 | 6 | 0 |
| 2026-01 | 8 | 8 | 0 |
| 2026-02 | 6 | 6 | 0 |
| 2026-03 | 8 | 6 | 2 |
Key Insight: Trial activity peaked in 2026-01 with 8 updates. Active/recruiting trials consistently reflect sustained research investment in Multiple System Atrophy (MSA) therapeutic development.
Therapeutic Mechanism Coverage
Mermaid diagram (expand to render)
Mermaid diagram (expand to render)
| Mechanism Cluster | Trial Count | Share |
|---|---:|---:|
| [Genetic / gene-targeted](/mechanisms/genetic-risk-factors) | 21 | 10.8% |
| [Alpha-synuclein pathology](/proteins/alpha-synuclein) | 17 | 8.8% |
| [Mitochondrial biology](/mechanisms/mitochondrial-dysfunction-ad) | 15 | 7.7% |
| [Amyloid biology](/mechanisms/amyloid-biology) | 5 | 2.6% |
| [Neurotransmitter systems](/cholinergic-hypothesis-and-neurotransmitter-systems-in-alzheimers-disease) | 4 | 2.1% |
| [Neuroinflammation](/mechanisms/neuroinflammation) | 4 | 2.1% |
| [Metabolic pathways](/insulin-resistance-and-metabolic-dysfunction-in-alzheimers-disease) | 2 | 1.0% |
| [Synaptic dysfunction](/mechanisms/synaptic-dysfunction) | 2 | 1.0% |
Mechanism coverage should be interpreted as a directional signal from registry metadata, not a complete map of all preclinical and translational investment streams.
| Sponsor Type | Trial Count | Share |
|---|---:|---:|
| Academic/Medical | 109 | 56.2% |
| Other | 47 | 24.2% |
| Industry | 32 | 16.5% |
| Public (NIH/Gov) | 4 | 2.1% |
| Foundation/Nonprofit | 2 | 1.0% |
Top sponsors by trial volume:
| Sponsor | Trial Count | Share |
|---|---:|---:|
| University Hospital, Bordeaux | 9 | 4.6% |
| Vanderbilt University Medical Center | 9 | 4.6% |
| Vanderbilt University | 9 | 4.6% |
| University Hospital, Toulouse | 6 | 3.1% |
| NYU Langone Health | 5 | 2.6% |
| Massachusetts General Hospital | 3 | 1.5% |
Gap Signals and Priority Research Areas
Late-stage translation bottleneck: Only 7.7% of the portfolio has reached Phase 3/4, indicating significant attrition between proof-of-concept and confirmatory programs.
Underrepresented mechanism areas: Lower-share clusters include [Amyloid biology](/mechanisms/amyloid-biology), [Neurotransmitter systems](/cholinergic-hypothesis-and-neurotransmitter-systems-in-alzheimers-disease), [Neuroinflammation](/mechanisms/neuroinflammation), [Metabolic pathways](/insulin-resistance-and-metabolic-dysfunction-in-alzheimers-disease), suggesting potential gaps in therapeutic coverage.
Combination strategy gap: Combination-therapy signals remain limited (0.0%), despite multi-pathway disease biology suggesting potential synergies.
Biomarker deployment: Biomarker-forward designs account for 14.4% of trials, supporting further endpoint standardization and earlier patient stratification.Quarterly Update Notes
This landscape is designed for recurring quarterly updates. Each cycle should include a refresh of trial records, a rerun of sponsor-type and mechanism-gap summaries, and a brief adjudication of whether the observed distribution reflects true scientific opportunity or only metadata coverage effects in public registries. Where possible, this page should be interpreted together with detailed pages in [Clinical Trials Index](/clinical-trials), disease pages, and mechanism pages to avoid over-indexing on simple count-based proxies.
See Also
- [Multiple System Atrophy (MSA)](/diseases/multiple-system-atrophy)
- [Clinical Trials Index](/clinical-trials)
- [Investment Landscape Index](/alzheimers-disease-investment-landscape)
- [Research Priorities in Neurodegenerative Disease](/gaps/research-priorities)
External Links
- [ClinicalTrials.gov — Multiple System Atrophy (MSA)](https://clinicaltrials.gov/search?cond=Multiple+System+Atrophy)
- [NIH Categorical Spending Dashboard](https://report.nih.gov/funding/categorical-spending#/)
- [NINDS — Multiple System Atrophy](https://www.ninds.nih.gov/health-information/disorders/multiple-system-atrophy)
- [MSA Coalition Research](https://www.multiplesystematrophy.org/research-resources)
References
Unknown, ClinicalTrials.gov condition search for Multiple System Atrophy (MSA) (n.d.)
Unknown, NIH Categorical Spending Dashboard (n.d.)
Unknown, ClinicalTrials.gov Neurodegenerative Disease Search (n.d.)
Unknown, FDA Drug Development and Approval Process (n.d.)
Unknown, ClinicalTrials.gov Glossary and Data Element Definitions (n.d.)